Published January 19, 2022 | Version v1
Journal article Open

Disrupting N-glycan expression on tumor cells boosts chimeric antigen receptor T cell efficacy against solid malignancies

Creators

  • 1. Innovative Immunotherapies Unit, Division of Immunology, Transplantation and Infectious Diseases, IRCCS San Raffaele Scientific Institute
  • 2. Lipid Signaling in Cancer and Metabolism Unit, Division of Experimental Oncology, IRCCS San Raffaele Scientific Institute AND Department of Molecular Biotechnology and Health Sciences, Molecular Biotechnology Center, University of Turin
  • 3. Center for Omics Sciences, IRCCS San Raffaele Scientific Institute
  • 4. Experimental Hematology Unit, Division of Immunology, Transplantation and Infectious Diseases, IRCCS San Raffaele Scientific Institute
  • 5. San Raffaele Telethon Institute for Gene Therapy, IRCCS San Raffaele Scientific Institute
  • 6. Pathology Unit, Division of Experimental Oncology, IRCCS San Raffaele Scientific Institute
  • 7. Hematology and Hematopoietic Stem Cell Transplantation Unit, IRCCS San Raffaele Scientific Institute

Description

Science Translational Medicine research article reporting that reducing the expression of N-glycans on tumor cells enhances the therapeutic potential of chimeric antigen receptor T cells against solid tumors

Notes

Accepted version before final editing. Find the final version at https://www.science.org/doi/10.1126/scitranslmed.abg3072

Files

Greco STM 2022_OA_accepted before final editing.pdf

Files (3.5 MB)

Additional details

Funding

CARAMBA – SLAMF7-CAR T cells prepared by Sleeping Beauty gene-transfer for immunotherapy of multiple myeloma – a rare hematologic disease 754658
European Commission
EURE-CART – EURopean Endeavour for Chimeric Antigen Receptor Therapies 733297
European Commission